CRYGD

Across TCGA pan-cancer cohorts, CRYGD RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated CRYGD data layer compared with 6 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher CRYGD RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated CRYGD expression acts as an unfavorable survival marker, although some lineages such as HNSC and PRAD show a favorable association.

MESO, KIRC, and BLCA are the cancer types where CRYGD RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	All	0.172	0.394	<.001	162	view →
KIRC	DFS	Tertile	IV	0.315	0.641	.005	90	view →
BLCA	DFS	Tertile	III,IV	0.275	0.473	<.001	87	view →
HNSC	OS	Tertile	III,IV	0.939	0.725	.009	60	view →
DLBC	OS	Tertile	All	0.395	0.878	.001	45	view →
UCS	OS	Tertile	IV	0.294	0.664	.012	36	view →
LAML	DFS	Median	All	0.250	0.493	.001	26	view →
LGG	OS	Quartile	All	0.811	0.940	<.001	24	view →
READ	DFS	Tertile	III,IV	0.174	0.747	.005	18	view →
THYM	DFS	Quartile	All	0.565	0.928	.008	17	view →
THCA	DFS	Tertile	III,IV	0.276	0.762	.042	12	view →
SARC	OS	Tertile	All	0.630	0.872	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

CRYGD–MESO (DFS)

Open the MESO breakdown →